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Abstract
Introduction: It is uncertain whether timeliness improves clinical outcomes in lung cancer patients. The goal of the study
was to analyse the influence  of patient’s and doctor’s delays on survival of unselected population of  NSCLC patients.
Material and methods: From 1995 to 1998, 8705 squamous cell lung cancer patient’s and 1881 adenocarcinoma patient’s
were registered in Pulmonary Outpatients Clinics in all parts of Poland and subsequently in National Tuberculosis and Lung
Diseases Research Institute Register (NTLDRIR).
Results: The median time from first symptom(s) to the beginning of a treatment was 92 days (mean —138.5 days).The median
waiting time between first symptom(s) and first visit to a doctor’s was 30 days (mean 57 days) and from first visit  to a doctor’s to
referral to a  chest physician — was 17 days (mean 41days). Diagnosis of the NSCLC was established in a mean time of 71 days
(median 40 days), but chest physician diagnosed patients in a mean time of 51days (median 28 days).
The multivariate analysis revealed that ECOG performance status (PS) 2 (HR = 1.4) and 3+4 (HR = 2.23), clinical stage of the
disease II (HR = 1.32), III (HR = 1.41), and IV (HR = 1.82) were independent  negative  predictors of  survival. Non-surgically treated
patients had worse prognosis than patients treated surgically (HR = 3.03). Lack of patient’s delay had a significant positive impact on
survival (HR = 0.88), particularly for patients in PS 0+1 (HR = 0.9) and 3+4 (HR = 0.9). Lack of doctor’s delay was a negative
predictive factor of survival (HR = 1.14). It was observed particularly in patients in performance status 2  (HR = 1.28).
Conclusions: The patient’s delay and lack of doctor’s delay had a negative  impact  on survival of NSCLC patients.
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Streszczenie
Wstęp: Nie jest w pełni ustalonym, na ile opóźnienie diagnostyki i leczenia  niedrobnokomórkowego raka  płuca (NDRP) ma
wpływ na przeżycie chorych. Celem  badania było ustalenie wpływu opóźnienia zależnego od chorego i zależnego od lekarza
na przeżycie chorych na NDRP w niewyselekcjonowanej populacji.
Materiał i metody: W okresie od 1995 do 1998  roku 8705 chorych na raka  płaskonabłonkowego i 1881 chorych na raka
gruczołowego płuca było  zarejestrowanych w Rejestrze Instytutu Gruźlicy i Chorób Płuc.
Wyniki: Mediana czasu pomiędzy wystąpieniem pierwszych objawów a rozpoczęciem leczenia wynosiła 92 dni (śr. 138,5
dnia). Mediana czasu  pomiędzy wystąpieniem pierwszych objawów a zgłoszeniem się do lekarza opieki podstawowej
wynosiła 30 dni (śr. 57 dni), a mediana czasu pomiędzy zgłoszeniem się do lekarza a wizytą u specjalisty chorób płuc —
17 dni (śr. 41 dni). Rozpoznanie raka płuca ustalone było średnio w ciągu 71dni (mediana 40 dni),  Czas w jakim lekarze
chorób płuc rozpoznawali raka płuca wynosił średnio 51 dni (mediana 28 dni). Analiza  wieloczynnikowa  wykazała, że stan
sprawności 2 w  skali  ECOG (HR = 1,4), 3+4 (HR = 2,23), stopień zaawansowania klinicznego nowotworu II (HR = 1,32),
III (HR = 1,41), IV (HR = 1,82) są niezależnymi czynnikami wpływającymi na przeżycie. Brak leczenia chirurgicznego był
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Introduction
Lung cancer, at the end of XX millenium, is
the most frequently diagnosed cancer in Poland
and worldwide [1–3]. In the European Union abo-
ut 200,000 new cases of lung cancer and 140,000
lung cancer deaths are recorded each year [1–5].
During the last few years about 24,000 cases of lung
cancer were diagnosed in our country yearly [5].
In Poland lung cancer incidence has risen drama-
tically for several decades; however, from the be-
ginning of the nineties stabilisation of the inciden-
ce in men was noticed, but there is a constant in-
crease of lung cancer incidence in women [5]. The
overall 5-year survival for patients with lung can-
cer is very low and varies between 15 % in the USA
and Austria, through 6.2% in Poland, to 6% in
Denmark [4–8]. It is well known that NSCLC pa-
tients with limited disease and in good performan-
ce status have better prognosis than those with
extensive disease and bad performance status.
NSCLC is a highly progressive disease, so it seems
reasonable that fast diagnosis and administration
of treatment ought to have an impact on survival
[9–14]. Recently many studies providing documen-
tation of the management process and outcome of
NSCLC patients have been published [15–37].
Many of them presented series of hospital-based
populations, particularly those treated by surgery,
but very few presented patient’s and doctor’s de-
lays in huge, unselected populations of lung can-
cer patients. The impact of patient’s and doctor’s
delays on survival was the subject of selected pa-
pers [22, 30, 31, 33–37].
The British Thoracic Society and Joint Colle-
giate Council for Oncology, the UK National He-
alth Service Cancer Plan, and the American Colle-
ge of Chest Physicians have made recommenda-
tions on the times for referrals and waiting in ma-
nagement pathways to improve care for lung can-
cer patients [38–40]. A 7-day period is recommen-
ded for referral to a chest physician and 2 weeks
for establishing diagnosis.
niezależnym negatywnym czynnikiem rokowniczym (HR = 3,03). Brak opóźnienia ze strony chorego wpływał pozytywnie na
rokowanie (HR = 0,88), szczególnie u chorych w stanie sprawności 0+1 w skali ECOG (HR = 0,9) oraz 3+4 (HR = 0,9).
Brak opóźnienia zależnego od lekarza znacząco negatywnie korelował z przeżyciem chorych (HR = 1,14). Szczególnie
dotyczyło to chorych w stanie sprawności 2 (HR = 1,28).
Wnioski: Brak opóźnienia ze strony chorego wpływa pozytywnie na przeżywalność  chorych na NDRP. Natomiast nie
obserwowano tego typu zależności dla opóźnienia  zawiązanego z procesem diagnostycznym, a wręcz przeciwnie chorzy
dłużej  diagnozowani  charakteryzowali się lepszą przeżywalnością.
Słowa kluczowe: rak niedrobnokomórkowy płuca, opóźnienie zależne od chorego, opóźnienie zależne od lekarza, przeżycie,
rokowanie
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The Polish health care system is generally pu-
blic. It is based on primary care and a special network
of Pulmonary Outpatients Departments and Pulmo-
nary Hospitals. The primary care is accessible quite
easily. A visit with a specialist requires referral by
a general practitioner; however, there are some pa-
tients who are immediately hospitalized. The costs
of healthcare are covered by the government.
The goal of this study was to assess prospecti-
vely the delay due to patients and doctors and its
impact on survival of an unselected population of
NSCLC patients registered in Pulmonary Outpa-
tient Departments in all parts of Poland.
Material and methods
From 1995 to 1998 data on 8705 of squamous
cell lung cancer patients and 1881 adenocarcino-
ma patients registered in Pulmonary Outpatient De-
partments from all parts of Poland were collected
in the Register of the National Tuberculosis and
Lung Diseases Research Institute (NTLDRI). The
diagnosis of lung cancer was based on positive hi-
stological or cytological examinations (according to
WHO criteria available at the time of the study). Data
regarding gender, age, histological type of lung can-
cer, performance status according to ECOG scale,
stage of the disease (TNM scale), treatment, survi-
val, and delay due to patients and doctors were re-
corded by using a standardised questionnaire. From
1996 to 1998 the dates of first visit with a specialist
and first bronchoscopy were noted as well. Every
six months, follow-up information was obtained.
Survival was assessed as the time between
diagnosis and date of death or last visit. Dates of
death were confirmed in the Central Address Bu-
reau at the end of 2003. The diagnosis of lung can-
cer was based on positive histological or cytologi-
cal examination (according to WHO criteria ava-
ilable at the time of the study).
Patient‘s delay was defined as the time betwe-
en first symptom(s) and the time of first visit to
a doctor. Sufficient information for analysis of
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patient’s delay was available for 7358 patients.
Doctor’s delay was defined as the time between first
visit to a doctor and treatment administration. This
information was available from 6384 patient records.
Therapy delay was defined as the time between dia-
gnosis and start of treatment. Also, time between first
visit to a doctor and first contact with a specialist,
time between first visit with the specialist and bron-
choscopy, diagnosis, and therapy were recorded.
Univariate and multivariate analysis by Cox
proportional hazards ratio model and log-rank test
were used to test the significance of prognostic fac-
tors including gender, age, stage, and performan-
ce status, and patient’s and doctor’s delays. A p va-
lue < 0.05 was considered as significant.
Results
The patients’ characteristics are presented in
Table 1. A total of 1064 (12%) women and 9322
(88%) men were included in this study. There were
1392 (13.2%) patients below 50 years old and 9194
(86.8%) patients were over 50 years old. Performan-
ce status 0+1 in ECOG scale was noticed in 5617
(58.1%) patients, 2 in 2989 (31%) patients, and 3+4
in 1048 (10.9%) NSCLC patients. The first clinical
stage of NSCLC was observed in 2464 (28.4%) pa-
tients, II in 1240 (14.3%), III in 3602 (41.5%), and
IV in 1369 (15.8%). Regarding performance status
and clinical stage of the disease, there was no dif-
ference between men and women. Surgical treat-
ment was applied in 2472 (31.2%) patients, and
535 (6.8%) of them were treated by surgery with
chemoradiotherapy. Radiotherapy or radiochemo-
therapy was administered to 1203 (15.4%) patients,
chemotherapy to 1937 (24.7%) patients, 2369
(30.2%) patients were treated symptomatically, and
422 (5.4%) refused therapy.
The delays observed in each stage of the inve-
stigative process are detailed in Table 2. The mean
total delay from first symptoms to treatment was
138 days (median 92 days). The mean patient’s de-
lay was 57 days (median 30 days). The mean wa-
iting time between first visit to a doctor and dia-
gnosis was 32 days (median 40 days). Fifty per cent
of patients were treated during the first 6 days after
diagnosis, but the mean time between diagnosis to
start of therapy was 32 days. The mean time from
first contact with a doctor until the date of first
appointment to chest physician (specialist) was 41
days (median 17 days). Chest physicians diagno-
sed fifty per cent of patients during 28 days, but
Table 1. Characteristics of NSCLC patients
Tabela 1. Charakterystyka chorych na raka niedrobnokomórkowego płuca
All Men Women
Age 10586 (100%) 9322 1264
Below 50 years 1392 (13.2%) 1099 (11.8%) 293 (23.2%)*
Over 50 years 9194 (86.8%) 8223 (88.2%) 971 (76.8%)
Performance status
0+1 5617 (58.1%) 4923 (58.1%) 694 (59.6%)
2 2989 (31%) 2660 (31.1% 329 (28.2%)
3+4 1048 (10.9%) 906 (10.7%) 142 (12.2%)
Clinical stage
I 2464 (28.4%) 2149 (28.1%) 315 (30%)
II 1240 (14.3%) 1107 (14.45%) 133 (12.6%)
III 3602 (41.5%) 3187 (42%) 415 (39.4%)
IV 1369 (15.8%) 1179 (15.45%) 190 (18%)
Treatment
Surgery 1937 (18.3%) 1641 (23.8%) 296 (31.9%)*
Surgery + combined 535 (6.8%) 445 (6.5%) 90 (9.7%)*
Chemoradiotherapy + radiotherapy 1203 (15.4%) 1076 (15.6%) 127 (13.8%)**
Chemotherapy 1365 (24.7%) 1213 (17.6%) 152 (16.3%)
Supportive care 2369 (30.2%) 2136 (30.9%) 233 (25%)*
Refused 422 (5.4%) 389 (5.6%) 33 (3.5%)*
*p < 0.001, **p < 0.05
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the mean specialist’s delay was 51 days. Additio-
nally, fifty per cent of patients had a bronchosco-
py within 11 days (mean 30 days). It should be un-
derlined that there were many cases diagnosed
without any delays; however, there were some
patients who had a very long period of symptoma-
tic disease or who waited for proper diagnosis for
several months.
Univariate analysis of prognostic factors that can
influence survival revealed that male gender (hazard
ratio — HR = 1.2), age over 50 years (HR = 1.22),
performance status 2 (HR = 1.74), and 3+4 (HR =
= 2.83), clinical stage of the disease II (HR = 1.49),
III (HR = 1.92), and IV (HR = 2.9) were significant
adverse predictors of survival. Patients in whom
surgery was applied had better prognosis than tho-
se receiving radiochemotherapy (HR = 2.34),
chemotherapy (HR = 3.03), and those treated symp-
tomatically (HR = 4.11) (Tab. 3). Lack of patient’s
delay had a positive (HR = 0.81) impact on survival,
but lack of doctor’s delay had a negative (HR = 1.18)
impact on survival.
Multivariate analysis of survival revealed that
performance status 2 (HR = 1.47), 3+4 (HR = 2.23),
clinical stage of the disease II (HR = = 1.32), III
(1.41) and IV (HR = 1.82), nonsurgical treatment
(HR = 2.65), and lack of doctor’s delay (HR = 1.14)
were negative prognostic factors, but lack of pa-
tient’s delay (HR = 0.88) was a positive progno-
stic factor (Tab. 4).
Performance status of patients was one of the
most powerful prognostic variables identified in
our study and was tightly connected with thera-
py. Therefore, multivariate analysis of previously
presented factors on groups of patients divided ac-
cording to performance status was performed (Tab.
5). Type of treatment and clinical stage of the di-
sease were significant predictors of survival. Ho-
wever, female gender and younger age were not
Table 3. Hazard ratio for death in NSCLC patients
— univariate analysis
Tabela 3. Analiza jednoczynnikowa ryzyka zgonu pacjentów
z rakiem niedrobnokomórkowym płuca
HR P value
Gender
Women 1.0
Men 1.2 0.001
Age
Below 50 years 1.0
Over 50 years 1.22 0.001
Treatment
Surgical 1.0
Chemoradiotherapy 2.34 0.001
Chemotherapy 3.03 0.001
Symptomatically 4.11 0.001
Refused 2.81 0.001
Performance status
0+1 1.0
2 1.74 < 0.001
3+4 2.83 < 0.001
Clinical stage
1 1.0
2 1.49 0.001
3 1.92 0.001
4 2.9 0.001
Patient’s delay
Over 30 days 1.0
Below 30 days 0.81 0.001
Doctor’s delay
Over 52 days 1.0
Below 52 days 1.18 0.001
Table 2. The various delays (days) in NSCLC patients
Tabela 2. Opóźnienia zależne od chorego i od lekarza u pacjentów z rakiem niedrobnokomórkowym płuca
Delays Number of patients Mean ± SD Median Low quartile High quartile
(days) (days)
Patient’s delay 7358 56.7 ± 117.3 30 9 61
First visit to the doctor — diagnosis 9274 32 ± 67.6 40 20 75
First visit to the doctor — first visit to the specialist 4824 40.6 ± 85.6 17 9 36
First visit to specialist — bronchoscopy 5279 29.1 ± 67.4 11 7 24
First visit to the specialist — diagnosis 5794 51.3 ± 91.5 28 16 47
Diagnosis — therapy 6944 32 ± 67.6 6 0 31
Symptom (s) — diagnosis 9537 116.2 ± 148.8 75 44 131
Symptom (s) — therapy 6289 138.5 ± 166.4 92 52 165
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found as factors influencing survival. Lack of pa-
tient’s delay had significant positive impact on su-
rvival in NSCLC patients in good PS (0+1)
(HR = 0.9) and bad PS (3+4) (HR = 0.9). Negative
impact on survival was observed in the group of
patients in medium performance status with a lack
of doctor’s delay (HR = 1.28).
Discussion
The delays: due to patients, in diagnosis, and
treatment, may result in worse clinical outcome.
On the other hand, these delays can influence the
psychosocial morbidity of patients with lung can-
cer. The overall survival of lung cancer patients is
very low, i.e. less than 40 % survived one year and
6–15% of them survived 5 years [2–5, 7]. Surgery
is still the only treatment with the potential of cure
for lung cancer, but only 15–30% of patients are
operated on [6–8, 10, 11, 14]. The survival benefit
depends on the performance status and clinical sta-
ge of the disease. It has been demonstrated that 70–
–75% of patients in clinical stage I of lung cancer
survived 5 years. The corresponding percentages of
patients in clinical stages II and III surviving 5 years
were 35% and 5%, respectively [6, 7, 14].
In Poland during the last 10 years the percen-
tage of patients undergoing surgical treatment has
been constantly increasing. In 1990–1995 about
17% of patients received surgical treatment [7, 8];
however, in the examined group of patients regi-
stered in NTLDRIR (1995–1998) — 25% of pa-
tients were treated by surgery. This was probably
due to better medical service of Pulmonary De-
partments. Additionally, there was better coope-
ration with thoracic surgery departments, which
were in many cases closely connected with pul-
monary departments.
Calculations of curves of tumour growth re-
vealed that in the late phase the tumour volume
expanded rapidly. The detection period of a tumo-
ur less than 2 cm is very tight. Therefore, many
patients are observed in advance disease stage. It
seems that delays in diagnosis and therapy may
influence survival.
In our study, patients' delays varied widely,
but the median delay was comparable with that ob-
served in many European countries and the USA
[26, 28, 30, 33–37].
The first symptoms of lung cancer are often
recognised as an infection or are connected with
age or other coexisting disease(s) [29, 41]. NSCLC
is a highly progressive disease and when the symp-
toms appear the disease is already advanced. In our
study it was shown that the lack of delay from first
symptoms to first visit to the doctor had a positive
impact on survival of NSCLC patients, both for
patients with good and bad performance status.
Christensen et al. revealed that delay before final
treatment of NSCLC patients had an impact on
preoperative stage of the cancer, but Billing et al.
did not observe such a correlation [17, 18].
A systematic review of the data presented in
the literature showed that median time from first
visit to a doctor to referral to a specialist vary from
13 days to 33 days, which is longer than recom-
mended [22, 23, 30, 33–37]. In our unselected po-
pulation the median referral time was 17 days.
Nevertheless, in some patients the time between
first visit to a doctor and the visit to a specialist
was rather long, influencing the mean delay repor-
ted in this study. It may be due to technical diffi-
culties, additional diseases, problems with coope-
ration, low suspicion of cancer - particularly in
younger patients (more than 13 % were below 50
Table 4. Multivariate analysis of hazard ratio for death of
NSCLC patients
Tabela 4. Analiza wieloczynnikowa ryzyka zgonu pacjentów
z rakiem niedrobnokomórkowym płuca
HR P value
Gender
Women 1.0
Men 1.08 0.115
Age
Below 50 years old 1.0
Over 50 years old 1.02 0.244
Treatment
Surgical 1.0
Non-surgical 3.03 0.001
Performance status
0+1 1.0
2 1.47 0.001
3+4 2.23 0.001
Clinical stage
1 1.0
2 1.32 0.001
3 1.41 0.001
4 1.82 0.001
Patient’s delay
Over 30 days 1.0 0.001
Below 30 days 0.88
Doctor’s delay
Over 42 days 1.0 0.001
Below 42 days 1.14
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Table 5. Multivariate analysis of hazard ratio for death in NSCLC patients according to performance status
Tabela 5. Analiza wieloczynnikowa ryzyka zgonu pacjentów z rakiem niedrobnokomórkowym płuca zależna od stanu sprawności
Performance status Performance status Performance status
0+1  2  3+4
HR P value HR P value HR P value
Gender
Women 1.0 1.0 1.0
Men 1.12 0.086 1.01 0.933 1.08 0.557
Age
Below 50 years old 1.0 1.0 1.0
Over 50 years old 1.02 0.694 1.02 0.838 0.96 0.765
Treatment
Surgical 1.0 1.0 1.0
Non-surgical 2.63 0.001 2.66 0.001 3.52 0.001
Clinical stage
1 1.0 1.0 1.0
2 1.38 0.001 1.2 0.05 1.29 0.2
3 1.42 0.001 1.40 0.001 1.39 0.047
4 1.79 0.001 1.7 0.001 2.31 0.001
Patient’s delay
Over 30 days 1.0 0.037 1.0 0.156 1.0 0.037
Below 30 days 0.9 0.92 0.9
Doctor’s delay
Over 42 days 1.0 0.132 1.0 0.001 1.0 0.132
Below 42 days 1.07 1.28 1.07
years of age), and errors in interpretation of chest
X-rays [29, 41]. In Poland the incidence of tuber-
culosis was rather high at the time of investigation
(about 34.4/100,000), and in many patients over
60 years of age post-tuberculotic lesions might be
observed in chest radiological examinations cau-
sing misdiagnosis and diagnostic delay [42].
It was revealed in our data, as in others, that
well-known predictors such as clinical stage of the
disease, performance status, and type of therapy
had an impact on survival of NSCLC patients
[6, 8–10, 33–37]. Gender and age were found to be
significant factors influencing survival in univa-
riate analysis but not in multivariate analysis when
variables such as patient’s and doctor’s delays were
added to the model. When multivariate analysis
was performed on separate groups of patients di-
vided according to performance status, a longer
period with symptoms had a negative impact on
survival, but only for patients in good and bad per-
formance status. Unexpectedly, we revealed that
doctor’s delay had no impact on survival in patients
in good and bad performance status. Therefore,
NSCLC patients in medium performance status
with prolonged diagnosis and/or longer period to
treatment onset had a better prognosis. It is possi-
ble that in the group of patients in medium perfor-
mance status diagnostic procedures were applied
quickly to severely ill patients in whom even a very
fast diagnosis would not change the very bad pro-
gnosis. On the other hand, in this group of patients
the performance status, relatively not good, might
be connected with cancer or with concomitant di-
seases.
Olsson et al. in the review mentioned abo-
ve, identified 15 studies analysing the correla-
tion between patient’s and doctor’s delay and su-
rvival [30]. Eight of them showed no association
between timeliness and outcome. Others, among
them data from screening programmes, demon-
strated worse survival in patients with delayed
diagnosis [33–36]. Recently, Salomaa et al., Gould
et al., and Skaugh et al. also proved that timeliness
of diagnosis had a negative impact on survival in
unselected populations of non-small cell lung can-
cer patients [22, 27, 37].
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The results of this study indicated that pa-
tient’s and doctor’s delays were not as short as we
would like them to be. NSCLC is a very progressi-
ve disease. When the disease is symptomatic it is
often locally or generally advanced, so prolonged
periods of symptoms or diagnostic procedures only
slightly influence survival.
Analysis pointed out that to improve the out-
come of lung cancer patients we have to change
diagnostic procedures to reveal the disease at an
early stage [43–45].
Taking into consideration the doubling time
of lung cancer cells observed, delays seem unac-
ceptable. Among patients who were diagnosed
for a longer period of time there were some who
were potentially operable at the time of first
symptoms or visit, but not at the time of diagno-
sis. Also, the diagnostic process, which lasts for
several months, has a negative influence on pa-
tients and their families.
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